]>
IRCT2016060628299N1 IRCT 2016-07-13 Kermanshah University of Medical Sciences The effect of quercetin supplementation on nonalcoholic fatty liver disease The effect of quercetin supplementation on liver enzymes, inflammation indices, lipid profile and body composition, acompaind by colori control in nonalcoholic fatty liver disease: A randomized, double-blind, pilot study 2016-07-10 anticipated 110 Complete https://irct.ir/trial/22980 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive. N/A Non Alcoholic Fatty Liver Disease. Intervention 1: Sigma quercetin supplements, 500 mg per day for 55 people in the intervention group for three monthsوBe taken on an empty stomach. Intervention 2: placebo supplement containing starch but looks completely like the original supplementation for placebo group received 500 mg per day for 55 people for three months,Be taken on an empty stomach.
public Mahboobe Hosseinikia
Faculty of Health, ISAR Field next to Farabi Hospital
Kermanshah Iran (Islamic Republic of) +98 83 3422 1215 M.hosseinikia@yahoo.com Kermanshah University of Medical Sciences, School of Public Health scientific Yahya Pasdar
Faculty of Health, ISAR Field next to Farabi Hospital
Kermanshah Iran (Islamic Republic of) +98 83 3826 2005 yahya.pasdar@kums.ac.ir Faculty of Health, ISAR Field next to Farabi Hospital, Kermanshah University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria include: a willingness to participation; age 18-65 years; non-alcoholic fatty liver diagnosed by ultrasonography and liver function test Tests( Alanine transaminase and Aspartate transaminase (more than 30u/l in men and more than 20u/l in women)) ; Lack of alcohol abuse (taking more than 10 grams per day for women and more than 30 grams per day for men); Body mass index equal to or greater than 40Kg/M2; Lack of other acute and chronic liver disorders (hepatitis B and C, etc.); Wilson's disease; cirrhosis; no history of biliary tract disease; acute heart failure disease; renal; pulmonary; infectious diseases; diabetes; cancer; inherited disorders affecting liver condition (iron storage disease, etc.); the absence of pregnancy and lactation; disease related to thyroid disorders; No history of weight loss surgery in the past year; the absence of lose weight in the past three months and In general, lack of increase or decrease in weight regimes during the three months prior to sampling; Autoimmune diseases such as primary biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis; Non-use of antioxidant supplements during one month prior to sampling; Lack of use of effective drugs against weight during the three months prior to sampling; Do not use multivitamin-minerals and drugs that are most likely associated with this disease(Antiepileptic drugs, amiodarone, corticosteroids, phenytoin, lithium, roacutan, tamoxifen, methotrexate, aspirin, 5-fluorouracil, zidovudine, a synthetic estrogen, inhibitors of hydroxymethyl glutaryl coa reductase and etc);Lack of exposure to pesticides and insecticides such as: carbon tetrachloride; trichloroethylene; Avoiding the use of drugs that are likely to overlap with quercetin; including anticoagulants, inhibitors of CYP3A4 and .... Exclusion criteria included: Not wanting to continue working; diseases that require special treatment; Reduction of more than 10% of baseline body weight during the intervention period; not consumption of more than 10% of the supplements in any follow-up period and in general, any inconsistent with the inclusion criteria 18 years 65 years Both K76.0 Fatty (change of) liver, not elsewhere classified Treatment - Drugs Treatment - Drugs Sigma quercetin supplements, 500 mg per day for 55 people in the intervention group for three monthsوBe taken on an empty stomach placebo supplement containing starch but looks completely like the original supplementation for placebo group received 500 mg per day for 55 people for three months,Be taken on an empty stomach Lipid profile. Timepoint: at first and the end of study. Method of measurement: enzymathic method. Liver enzymes. Timepoint: at first and the end of study. Method of measurement: enzymathic method. Inflammatory markers. Timepoint: at first and the end of study. Method of measurement: ELISA method. Body composition. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: BIA. Weight. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: With light clothing and using Seca scales with 100 gAccuracy. Height. Timepoint: Accuracy. Method of measurement: بدون کفش با استفاده از قد سنج سکا با دقت 0.1 سانتی متر. Waist circumference. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: Using a tape measure between the lowest gear and iliac crest with accuracy of 0.5 cm. Hip circumference. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: Using a tape measure at the bigest part of the hips. Kermanshah University of Medical Sciences Approved 2010-08-20 Kermanshah University of Medical Sciences Building No. 2, Shahid Beheshti Boulevard, Kermanshah Kermanshah Iran (Islamic Republic of)